{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:09:41Z","timestamp":1791421781172,"version":"4.3.3"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Imatinib mesylate (imatinib), a competitive inhibitor of the BCR-ABL tyrosine kinase, is highly effective against chronic myelogenous leukemia (CML) cells. However, because 20\u201330% of patients affected by CML display either primary or secondary resistance to imatinib, intentional activation of V\u03b39V\u03b42 T cells by phosphoantigens or by agents that cause their accumulation within cells, such as zoledronate, may represent a promising strategy for the design of a novel and highly innovative immunotherapy capable to overcome imatinib resistance. In this study, we show that V\u03b39V\u03b42 T lymphocytes recognize, trogocytose, and efficiently kill imatinib-sensitive and -resistant CML cell lines pretreated with zoledronate. V\u03b39V\u03b42 T cell cytotoxicity was largely dependent on the granule exocytosis- and partly on TRAIL-mediated pathways, was TCR-mediated, and required isoprenoid biosynthesis by zoledronate-treated CML cells. Importantly, V\u03b39V\u03b42 T cells from patients with CML can be induced by zoledronate to develop antitumor activity against autologous and allogeneic zoledronate-treated leukemia cells, both in vitro and when transferred into immunodeficient mice in vivo. We conclude that intentional activation of V\u03b39V\u03b42 T cells by zoledronate may substantially increase their antileukemia activities and represent a novel strategy for CML immunotherapy.<\/jats:p>","DOI":"10.4049\/jimmunol.0903454","type":"journal-article","created":{"date-parts":[[2010,2,12]],"date-time":"2010-02-12T21:43:54Z","timestamp":1266011034000},"page":"3260-3268","source":"Crossref","is-referenced-by-count":141,"title":["V\u03b39V\u03b42 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells"],"prefix":"10.1093","volume":"184","author":[{"given":"Matilde","family":"D\u2019Asaro","sequence":"first","affiliation":[{"name":"Dipartimento di Biopatologia e Metodologie Biomediche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"La Mendola","sequence":"additional","affiliation":[{"name":"Dipartimento di Biopatologia e Metodologie Biomediche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Di Liberto","sequence":"additional","affiliation":[{"name":"Dipartimento di Biopatologia e Metodologie Biomediche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Orlando","sequence":"additional","affiliation":[{"name":"Dipartimento di Biopatologia e Metodologie Biomediche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Todaro","sequence":"additional","affiliation":[{"name":"Dipartimento di Discipline Chirurgiche ed Oncologiche, Universit\u00e0 di Palermo , Palermo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Spina","sequence":"additional","affiliation":[{"name":"Dipartimento di Discipline Chirurgiche ed Oncologiche, Universit\u00e0 di Palermo , Palermo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[{"name":"Dipartimento di Biopatologia e Metodologie Biomediche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Meraviglia","sequence":"additional","affiliation":[{"name":"Dipartimento di Biopatologia e Metodologie Biomediche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Caccamo","sequence":"additional","affiliation":[{"name":"Dipartimento di Biopatologia e Metodologie Biomediche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Messina","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche, Universit\u00e0 degli Studi di Catania , Catania,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Salerno","sequence":"additional","affiliation":[{"name":"Dipartimento di Biopatologia e Metodologie Biomediche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche, Universit\u00e0 degli Studi di Catania , Catania,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche, Universit\u00e0 degli Studi di Catania , Catania,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Stassi","sequence":"additional","affiliation":[{"name":"Dipartimento di Discipline Chirurgiche ed Oncologiche, Universit\u00e0 di Palermo , Palermo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Jacques","family":"Fourni\u00e8","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut National de la Sant\u00e8 et de la Recherche M\u00e8dicale Unit\u00e9 563 , Hospital Purpan, Toulouse Cedex 03,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dieli","sequence":"additional","affiliation":[{"name":"Dipartimento di Biopatologia e Metodologie Biomediche"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,3,15]]},"reference":[{"key":"2026012806323500300_r1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment.","volume":"349","author":"Goldman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2026012806323500300_r2","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"2026012806323500300_r3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"2026012806323500300_r4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2026012806323500300_r5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ijc.20987","article-title":"Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.","volume":"116","author":"Sato","year":"2005","journal-title":"Int. J. Cancer"},{"key":"2026012806323500300_r6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ijc.20445","article-title":"Potential of human gammadelta T lymphocytes for immunotherapy of cancer.","volume":"112","author":"Kabelitz","year":"2004","journal-title":"Int. J. Cancer"},{"key":"2026012806323500300_r7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12032-007-9004-4","article-title":"Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.","volume":"25","author":"Saitoh","year":"2008","journal-title":"Med. Oncol."},{"key":"2026012806323500300_r8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.coi.2006.07.002","article-title":"Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.","volume":"18","author":"Bonneville","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"2026012806323500300_r9","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1126\/science.279.5357.1737","article-title":"Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells.","volume":"279","author":"Groh","year":"1998","journal-title":"Science"},{"key":"2026012806323500300_r10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","article-title":"Gammadelta T cells for immune therapy of patients with lymphoid malignancies.","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"key":"2026012806323500300_r11","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.4049\/jimmunol.175.8.5481","article-title":"V \u03b3 9V \u03b4 2 T cell response to colon carcinoma cells.","volume":"175","author":"Corvaisier","year":"2005","journal-title":"J. Immunol."},{"key":"2026012806323500300_r12","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human \u03b3\u03b4 T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res."},{"key":"2026012806323500300_r13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","article-title":"Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP.","volume":"144","author":"Roelofs","year":"2009","journal-title":"Br. J. Haematol."},{"key":"2026012806323500300_r14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2141.2005.05648.x","article-title":"Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth.","volume":"130","author":"Segawa","year":"2005","journal-title":"Br. J. Haematol."},{"key":"2026012806323500300_r15","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood-2003-01-0305","article-title":"The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.","volume":"102","author":"Kuroda","year":"2003","journal-title":"Blood"},{"key":"2026012806323500300_r16","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/sj.leu.2403949","article-title":"Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.","volume":"19","author":"Chuah","year":"2005","journal-title":"Leukemia"},{"key":"2026012806323500300_r17","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00262-007-0279-2","article-title":"Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.","volume":"56","author":"Mattarollo","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"2026012806323500300_r18","doi-asserted-by":"crossref","first-page":"7287","DOI":"10.4049\/jimmunol.0804288","article-title":"Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.","volume":"182","author":"Todaro","year":"2009","journal-title":"J. Immunol."},{"key":"2026012806323500300_r19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20030235","article-title":"Differentiation of effector\/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites.","volume":"198","author":"Dieli","year":"2003","journal-title":"J. Exp. Med."},{"key":"2026012806323500300_r20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cyto.a.20189","article-title":"A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry.","volume":"68","author":"Godoy-Ramirez","year":"2005","journal-title":"Cytometry A"},{"key":"2026012806323500300_r21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/08820130701674646","article-title":"Lipophilic fluorochrome trackers of membrane transfers between immune cells.","volume":"36","author":"Gertner-Dardenne","year":"2007","journal-title":"Immunol. Invest."},{"key":"2026012806323500300_r22","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.4049\/jimmunol.174.3.1717","article-title":"Profiling blood lymphocyte interactions with cancer cells uncovers the innate reactivity of human \u03b3 \u03b4 T cells to anaplastic large cell lymphoma.","volume":"174","author":"Poupot","year":"2005","journal-title":"J. Immunol."},{"key":"2026012806323500300_r23","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.4049\/jimmunol.173.11.6767","article-title":"Characterization of tumor reactivity of human V \u03b3 9V \u03b4 2 \u03b3 \u03b4 T cells in vitro and in SCID mice in vivo.","volume":"173","author":"Kabelitz","year":"2004","journal-title":"J. Immunol."},{"key":"2026012806323500300_r24","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1021\/jm801003y","article-title":"Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism.","volume":"51","author":"Simoni","year":"2008","journal-title":"J. Med. Chem."},{"key":"2026012806323500300_r25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.imlet.2007.03.002","article-title":"Human gammadelta T lymphocytes strip and kill tumor cells simultaneously.","volume":"110","author":"Gertner","year":"2007","journal-title":"Immunol. Lett."},{"key":"2026012806323500300_r26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000174688","article-title":"Lovastatin and simvastatin\u2014inhibitors of HMG CoA reductase and cholesterol biosynthesis.","volume":"77","author":"Alberts","year":"1990","journal-title":"Cardiology"},{"key":"2026012806323500300_r27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0022-2275(20)41954-6","article-title":"In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.","volume":"32","author":"Harwood","year":"1991","journal-title":"J. Lipid Res."},{"key":"2026012806323500300_r28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.7-6-481","article-title":"The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.","volume":"7","author":"Major","year":"2002","journal-title":"Oncologist"},{"key":"2026012806323500300_r29","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00000421-200212001-00003","article-title":"Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.","volume":"25","author":"Major","year":"2002","journal-title":"Am. J. Clin. Oncol."},{"key":"2026012806323500300_r30","first-page":"2394","article-title":"Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.","volume":"9","author":"Ibrahim","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"2026012806323500300_r31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02983531","article-title":"Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.","volume":"79","author":"Kimura","year":"2004","journal-title":"Int. J. Hematol."},{"key":"2026012806323500300_r32","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.","volume":"42","author":"Chen","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"2026012806323500300_r33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/0091270002239824","article-title":"The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.","volume":"43","author":"Skerjanec","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"2026012806323500300_r34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0014-5793(03)00483-6","article-title":"Microbial isoprenoid biosynthesis and human gammadelta T cell activation.","volume":"544","author":"Eberl","year":"2003","journal-title":"FEBS Lett."},{"key":"2026012806323500300_r35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells.","volume":"197","author":"Gober","year":"2003","journal-title":"J. Exp. Med."},{"key":"2026012806323500300_r36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.immuni.2004.11.012","article-title":"Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I.","volume":"22","author":"Scotet","year":"2005","journal-title":"Immunity"},{"key":"2026012806323500300_r37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"key":"2026012806323500300_r38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1074-7613(01)00168-6","article-title":"MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function.","volume":"15","author":"Das","year":"2001","journal-title":"Immunity"},{"key":"2026012806323500300_r39","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.174.3.1338","article-title":"Phosphostim-activated \u03b3 \u03b4 T cells kill autologous metastatic renal cell carcinoma.","volume":"174","author":"Viey","year":"2005","journal-title":"J. Immunol."},{"key":"2026012806323500300_r40","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.4049\/jimmunol.0900101","article-title":"Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells.","volume":"182","author":"Li","year":"2009","journal-title":"J. Immunol."},{"key":"2026012806323500300_r41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia"},{"key":"2026012806323500300_r42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-3083.2007.01963.x","article-title":"Lysis of a broad range of epithelial tumour cells by human \u03b3 \u03b4 T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.","volume":"66","author":"Wrobel","year":"2007","journal-title":"Scand. J. Immunol."},{"key":"2026012806323500300_r43","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2174\/092986708784310468","article-title":"Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.","volume":"15","author":"Caccamo","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"2026012806323500300_r44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-2478(02)00292-4","article-title":"Perforin-dependent killing of tumor cells by Vgamma1Vdelta1-bearing T-cells.","volume":"86","author":"Narazaki","year":"2003","journal-title":"Immunol. Lett."},{"key":"2026012806323500300_r45","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.4049\/jimmunol.174.8.4678","article-title":"\u03b3 \u03b4 T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism.","volume":"174","author":"Ponomarev","year":"2005","journal-title":"J. Immunol."},{"key":"2026012806323500300_r46","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1084\/jem.191.6.937","article-title":"Self-recognition of CD1 by \u03b3\/\u03b4 T cells: implications for innate immunity.","volume":"191","author":"Spada","year":"2000","journal-title":"J. Exp. Med."},{"key":"2026012806323500300_r47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-065X.2006.00468.x","article-title":"Self\/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?","volume":"215","author":"Thedrez","year":"2007","journal-title":"Immunol. Rev."},{"key":"2026012806323500300_r48","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","article-title":"Safety profile and anti-tumor effects of adoptive immunotherapy using \u03b3-\u03b4 T cells against advanced renal cell carcinoma: a pilot study.","volume":"56","author":"Kobayashi","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"2026012806323500300_r49","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.","volume":"37","author":"Abe","year":"2009","journal-title":"Exp. Hematol."},{"key":"2026012806323500300_r50","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00262-008-0491-8","article-title":"Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in \u03b39\u03b42 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.","volume":"57","author":"Bennouna","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"2026012806323500300_r51","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/184\/6\/3260\/62721044\/ji_0903454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/184\/6\/3260\/62721044\/ji_0903454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:36:10Z","timestamp":1769600170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/184\/6\/3260\/8007229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,3,15]]},"published-print":{"date-parts":[[2010,3,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.0903454","relation":{},"ISSN":["1550-6606","0022-1767"],"issn-type":[{"value":"1550-6606","type":"electronic"},{"value":"0022-1767","type":"print"}],"subject":[],"published-other":{"date-parts":[[2010,3]]},"published":{"date-parts":[[2010,3]]}}}